Development of 2-hydroxymethyl-3,5,6-trimethylpyrazine palmitate-loaded lipid emulsion: Formulation, optimization, characterization, pharmacokinetics, biodistribution and pharmacodynamics

Journal of Drug Targeting

Volumn 21, Issue 4, 2013, Pages 341-353

  Cao, Ran ^a   Li, Qian ^a   Li, Hui ^b,c   Chu, Ting ^a   Jin, Hui ^a   Mao, Sheng Jun ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

2 Hydroxymethyl 3,5,6 trimethyl pyrazine; Brain targeting; Cerebral ischemia; Lipid emulsion; Tetramethylpyrazine

Indexed keywords

2 HYDROXYMETHYL 3,5,6 TRIMETHYLPYRAZINE PALMITATE; LIPID EMULSION; PALMITIC ACID; PHOSPHATIDYLCHOLINE; POLOXAMER; PYRAZINE DERIVATIVE; SOYBEAN OIL; TETRAMETHYLPYRAZINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; EMULSIONS; HALF-LIFE; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE; PALMITATES; PYRAZINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84877104933     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.751536     Document Type: Article

References (34)

1. Jiang FR, Qian JC, Chen SY, et al. Ligustrazine improves atherosclerosis in rat via attenuation of oxidative stress. Pharm Bio 2011;49:856-63.
2. Wu HJ, Hao J, Wang SQ, et al. Protective effects of ligustrazine on TNF-alpha-induced endothelial dysfunction. Eur J Pharm 2012;574:365-9.
3. Cheng XC, Liu XY, Xu WF. Research progress of pharmacology of cardiovascular and cerebrovascular of tetramethylpyrazine. Chin J Hosp Pharm 2005;25:661-3.
4. Lv L, Jiang SS, Xu J, et al. Protective effect of ligustrazine against myocardial ischaemia reperfusion in rats: the role of endothelial nitric oxide synthase. Clin Exp Pharmacol 2012;39:20-7.
5. Xu R, Li Y, Huang X. Research progress of tetramethylpyrazine drug metabolism and pharmacokinetics. J Anhui TCM Coll 2002;21:58-61.
6. Zeng CY, Mei QX. ADRs induced by tetramethylpyrazine: literature analysis of 30 cases. China Pharm 2008;19:1908-10.
7. Shi J, Wang Y, Luo G. Ligustrazine phosphate ethosomes for treatment of Alzheimer's disease, in vitro and in animal model studies. AAPS Pharm Sci Tec 2012;13:485-92.
8. Zhao JH, Ji L, Wang H, et al. Microemulsion-based novel transdermal delivery system of tetramethylpyrazine: preparation and evaluation in vitro and in vivo. Int J Nanomed 2011;6:1611-19.
9. Mei D, Mao S, Sun W, et al. Effect of chitosan structure properties and molecular weight on the intranasal absorption of tetramethyl-pyrazine phosphate in rats. Eur J Pharm Biopharm. 2008;70:874-81.
10. Wei LJ, Marasinib N, Li G, et al. Development of ligustrazine-loaded lipid emulsion: formulation optimization, characterization and biodistribution. Int J Pharm 2012;437:203-12.
11. Zhao RL, Hou SX, Mao SJ, et al. Tissue distribution of tetramethylpyrazine intralipid in mice. Central South Pharm 2008;11:264-7.
12. Washington C. Stability of lipid emulsions for drug delivery. Adv Drug Deliv Rev 1996;20:131-45.
13. Lou YQ, Zhang H, Cao X, Chen ML. The pharmacokinetics and disposition of tetramethylpyrazine phosphate in dogs and rats. Acta Pharmaceutica Sin 1986;21:481-7.
14. Jiang J, Jiang GH, Ye YP, Wang SZ. The metabolism of TMPz in vivo. Acta Acad Med Sin 1993;15:79-82.
15. Chen XM, Xu SJ, Ma YW. Synthesis of 2-hydroxymethyl-3, 5, 6-trimethyl-pyrazine and observation of its affection on rheologic parameters. Chin J Med Chem 1996;6:254-6.
16. Chen XM, Cao YX, Li GW, et al. Effect of 2-hydroxymethyl-3, 5, 6-trimethyl-pyrazine on cardiovascular system. Chin J Pharm 1998;29:258-60.
17. Nishiwaki S, Nakayama T, Murata M, et al. Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation: macrophage-targeted steroid therapy. Int J Hematol 2012;95:428-33.
18. Gulati N, Gupta H. Parenteral drug delivery: a review. Recent Pat Drug Deliv Formul 2011;5:133-45.
19. Date AA, Nagarsenker MS. Parenteral microemulsions: an overview. Int J Pharm, 2008;355:19-30.
20. Chu T, Zhang Q, Li H, et al. Development of intravenous lipid emulsion of tanshinone IIA and evaluation of its anti-hepatoma activity in vitro. Int J Pharm 2012;424:76-88.
21. Shen QW, Mao SJ, Wu Y, et al. Synthesis of 2-hydroxy-methyl-3, 5, 6-trimethyl-pyrazine pPalmitate and preparation of intravenous emulsion. Chin Pharm J 2009;24:1874-7.
22. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989;20:84-91.
23. Tamilvanan S. Oil-in-water lipid emulsions: implications for parenteral and ocular delivering systems. Prog Lipid Res 2004; 6:489-533.
24. Brime B, Moreno MA, Frutos G, et al. Amphotericin B in oil-water lecithin-based microemulsions: formulation and toxicity evaluation. J Pharm Sci 2002;4:1178-85.
25. Shi S, Chen H, Cui Y, Tang X. Formulation, stability and degradation kinetics of intravenous cinnarizine lipid emulsion. Int J Pharm 2009;373:147-55.
26. Jumaa M, Kleinebudde P, Muller BW. Physicochemical properties and hemolytic effect of different lipid emulsion formulations using a mixture of emulsifiers. Pharm Acta Helv 1999;6:293-301.
27. Trotta M, Pattarinob F, Ignoni T. Stability of drug-carrier emulsions containing phosphatidylcholine mixtures. Eur J Pharma Biopharm 2002;53:203-8.
28. Ishii F, Sasaki I, Ogata H. Effect of phospholipid emulsi-fiers on physicochemical properties of intravenous fat emulsions and/or drug carrier emulsions. J Pharm Pharmacol 1990;42:513-15.
29. Gamon BL, Virden JW, Berg JG. The aggregation kinetics of an electrostatically stabilized dipalmitoyl phosphatidylcholine system. J Coil Int Sci 1989;132:125-37.
30. Chen X, Dong SN. Studies on the metabolites of tetramethylpyr-azine in rabbits. Acta Pharmaceutica Sinica 1996;31:617-21.
31. Yang Y, Li H, Gao K, et al. Simultaneous quantitation of dexamethasone palmitate and dexamethasone in human plasma by liquid chromatography/tandem mass spectrometry. J Chrom B 2008;862:119-24.
32. Liao SL, Kao TK, Chen WY, et al. Tetramethylpyrazine reduces ischemic brain injury in rats. Neurosci Lett 2004;372:40-5.
33. Kao TK, Ou YC, Kuo JS, et al. Neuroprotection by tetramethylpyr-azine against ischemic brain injury in rats. Neurochem Int 2006;48:166-76.
34. Zhu XL, Xiong LZ, Wang Q, et al. Therapeutic time window and mechanism of tetramethylpyrazine on transient focal cerebral ischemia/reperfusion injury in rats. Neurosci Lett 2009;449:24-7.